Company news

Curis, Inc. news in 2021

Curis, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Curis Appoints John A. Hohneker, M.D. To Board Of Directors

December 5, 2021

Curis Reports Third Quarter 2021 Financial Results and Business Update

November 8, 2021

Curis Announces New Preclinical Data for CI-8993 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

November 8, 2021

Curis Announces First Patient Dosed in Phase 1/2 Study of CA-4948 Combination Therapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

November 7, 2021

Curis to Release Third Quarter 2021 Financial Results and Hold Conference Call on November 9, 2021

November 1, 2021

Curis Announces New Preclinical Data Highlighting the Potential of CA-4948 in Multiple Hematologic Malignancies Presented at the AACR-NCI-EORTC Virtual Conference on Molecular Targets and Cancer Therapeutics

October 6, 2021

Curis Reports Second Quarter 2021 Financial Results

August 2, 2021

Curis to Release Second Quarter 2021 Financial Results and Hold Conference Call on August 3, 2021

July 26, 2021

Curis, Inc. Set to Join Russell 2000®, 3000® and Microcap® Indexes

June 24, 2021

Curis Announces Positive Updated Data from Ongoing Phase 1/2 Study of CA-4948 Monotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes

June 10, 2021

Curis, Inc. Announces 2021 Virtual Symposium: "VISTA: A New Immune Checkpoint in Cancer, Autoimmunity and Beyond"

May 31, 2021

Curis Reports First Quarter 2021 Financial Results

May 11, 2021

Curis to Release First Quarter 2021 Financial Results and Hold Conference Call on May 12, 2021

May 4, 2021

Curis Receives FDA Orphan Drug Designation for CA-4948 for the Treatment of AML and MDS

April 18, 2021

Curis Reports Fourth Quarter and Year-End 2020 Financial Results

March 15, 2021

Curis Announces Abstract for CA-4948 Accepted for Presentation at the American Association for Cancer Research Annual Meeting

March 9, 2021

Curis to Release Fourth Quarter 2020 Financial Results and Hold Conference Call on March 16, 2021

March 8, 2021

Curis Doses First Patient in Phase 1 Study of CA-4948 in Combination with Ibrutinib in Patients with Relapsed or Refractory Hematologic Malignancies

February 8, 2021

Curis Announces Initiation of Investigator-Sponsored Phase 2 LUCAS Study of CA-4948 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate-Risk Myelodysplastic Syndromes

February 1, 2021

Calls in 2021

Decks in 2021